Literature DB >> 1017722

Antifactor Xa activity measured with amidolytic methods.

O R Odegård, M Lie, U Abildgaard.   

Abstract

Methods for the assay of antifactor Xa activity in the presence and absence of heparin are described. Diluted plasma is incubated with bovine, activated factor X (Xa) in stage I, and remaining Xa is measured with the chromogene substrate Bz-Ile-Glu-Gly-Arg-pNA in stage II. In the presence of heparin, the inactivation is completed in 30 sec, and this method measures total Xa-inactivating capacity in diluted plasma (Method I). In a clincal material, this capacity showed a strong positive correlation (r=0.85) to the thrombin-inactivating capacity of diluted heparinized plasma (heparin cofactor activity) and apparently reflects antithrombin III (At-III) concentration. In the absence of heparin, the inactivation of factor xa occurs slowly. With an incubation of 5 min, about 25% of Xa is inactivated, and this assay reflects initial inactivation of Xa (Method II). With this method, a positive, but less strong correlation to the thrombin-inactivating capacity was found (r=0.58), indicating that inhibitors different from At-III accounts for a minor part of the initial inactivation. Determinations in plasma, in which At-III was removed by immunoadsorption, indicated that At-III accounts for about 80% of the initial inactivation. The results of the assays are not significantly influenced by varying concentrations of fibrinogen, fibrinogen degradation products or heparin in the test plasma.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1017722     DOI: 10.1159/000214145

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  9 in total

1.  Associated von Willebrand disease as a possible cause of lack of thrombosis in an AT III abnormality (AT III Trento).

Authors:  A Girolami; M G Cappellato; M A Vicarioto; S Casonato; F Marafioti
Journal:  Blut       Date:  1986-01

2.  Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").

Authors:  J E Sambrano; L J Jacobson; E B Reeve; M J Manco-Johnson; W E Hathaway
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

3.  Determination of antithrombin activity by an amidolytic and a clotting procedure.

Authors:  A Frigola; S Angeloni; A R Cerqueti
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

4.  Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

Authors:  J Y Borg; M C Owen; C Soria; J Soria; J Caen; R W Carrell
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

5.  Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease.

Authors:  A Girolami; F Fabris; G Cappellato; L Sainati; G Boeri
Journal:  Blut       Date:  1983-08

6.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.

Authors:  K A Bauer; T L Goodman; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells.

Authors:  O D Ratnoff; M M Emanuelson; N P Ziats
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

8.  Preoperative antithrombin III activities and lipoprotein concentrations as predictors of venous thrombosis in patients with fracture of neck of femur.

Authors:  J H Winter; A Fenech; B Bennett; A S Douglas
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

Review 9.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.